dasatinib + all-trans retinoic acid + sirolimus

Dasatinib + all-trans retinoic acid + sirolimus is an experimental combination therapy consisting of dasatinib (a small-molecule multikinase inhibitor targeting BCR-ABL, SRC family kinases, and others), all-trans retinoic acid (ATRA, a retinoid that induces differentiation in acute promyelocytic leukemia cells via retinoic acid receptor signaling), and sirolimus (an mTOR inhibitor that suppresses T-cell proliferation and cell growth). This triplet lacks a unique brand name and is investigated primarily in hematologic malignancies, leveraging dasatinib's activity against Philadelphia chromosome-positive leukemias, ATRA's differentiation effects, and sirolimus's antiproliferative and immunosuppressive actions to potentially enhance efficacy in resistant or high-risk leukemias. No specific developers are identified for this exact combination, and it remains in early investigational stages without regulatory approval.